AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

Initial results from the ALXN1210-TMA-314 Phase III trial showed that UK pharma major AstraZeneca’s Ultomiris (ravulizumab) ...

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

AstraZeneca now has 16 blockbuster medicines in its portfolio with sales exceeding $1 billion, including Tagrisso, Fasenra, Farxiga, Imfinzi, Lynparza, Calquence and Ultomiris. These drugs are ...

Meanwhile, sales of Ultomiris, the flagship of AstraZeneca's Rare Disease segment and the successor of Soliris, reached $1.05 billion in the first three months of 2025, increasing by 22.2% year-on ...

This approval positions J&J to challenge leading competitors in the myasthenia gravis market, such as AstraZeneca, which markets the monoclonal antibodies SOLIRIS and ULTOMIRIS. J&J will also be ...